 |
BioWorld-Insight-2010-10-18
Debating What's Needed for an Obesity Approval
Debating What's Needed for an Obesity Approval
Obesity's "big three" are top of mind these days, thanks to recent FDA panel rejections and upcoming FDA decision dates for Arena Pharmaceuticals Inc.'s Lorqess (lorcaserin) and Vivus Inc.'s Qnexa (phentermine/topiramate), as well as a pending panel for Orexigen Therapeutics Inc.'s Contrave (naltrexone SR/bupropion SR).